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Background: This study attempts to define clinical predictors of survival in patients with unresectable
pancreatic adenocarcinoma (UPA).
Methods: A retrospective study of 94 consecutive patients diagnosed with UPA from 2001 to 2006 was
performed. Using data for these patients, a symptom score was devised through a forward stepwise Cox
proportional hazards model based on four weighted criteria: weight loss of >10% of body weight; pain;
jaundice, and smoking. The symptom score was subsequently validated in a distinct cohort of 32 patients
diagnosed with UPA in 2007.
Results: In the original cohort, the overall median survival was 9.0 months (95% confidence interval [CI]
7.6–10.4). This altered to 10.3 months (95% CI 6.1–14.5) in patients with locally advanced disease, and
6.6 months (95% CI 4.2–9.0) in patients with distant metastasis. Median survival was 14.6 months (95%
CI 13.1–16.1) in patients with a low symptom (LS) score and 6.3 months (95% CI 4.1–8.5) in patients with
a high symptom (HS) score. A total of 73% of LS score patients survived beyond 9 months, compared
with only 38% of HS score patients (P < 0.001). The discrimination of the LS score was greater than that
of any conventional method, including imaging. The validation cohort confirmed the discriminative ability
of the symptom score for survival.
Conclusions: A simple and clinically meaningful point-based symptom score can successfully predict
survival in patients with UPA.
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Introduction
The vast majority of patients with pancreatic adenocarcinoma
present with unresectable disease as a result of either local inva-
sion or distant metastasis.1 Although significant life-prolonging
treatment remains evasive, the last decade has been associated
with improved survival in this group, although care is still prima-
rily aimed at palliative measures, including chemotherapy, the
supportive management of pain, the relief of biliary and duodenal
obstructive symptoms, cachexia and malnutrition.2–4
The efficacious management of jaundice itself has been shown
to significantly influence quality of life and even survival.5–7
Whereas surgical bypass had long been the strategy of choice for
the palliation of obstructive symptoms of the biliary tract, this
dogma was successfully challenged in the early 1990s, often in the
context of comparisons with endoscopic stenting.8,9 These studies
suggested that the surgical option of biliary decompression was
less favourable than that of endoscopic decompression with
plastic biliary stents with respect to early morbidity, although
mortality remained unaffected. However, in the longer term, the
surgical option was superior because of the absence of stent block-
age and cholangitis in the surgical group. This finding appears to
be true for patients who survive for 6 months. The advent of
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metal stents10 and, more recently, covered metal stents11 has sig-
nificantly prolonged their duration of patency. A more recent
cohort study utilizing metal biliary stents12 demonstrated a biliary
patency of 6–7 months in patients with malignant biliary obstruc-
tion. With such improvements in non-operative palliation tech-
niques, any possible benefit of bypass surgery can only occur if
survival is longer than the duration of metal stent patency. In
order to allow for optimal individualized patient care, it would
thus appear essential to identify which patients with unresectable
pancreatic adenocarcinoma (UPA) are likely to survive longer. To
date there is a paucity of data in the literature regarding factors
that predict the survival of patients with UPA prior to interven-
tion. The aim of this study was to identify simple clinical factors
that can help determine the prognosis in these patients.
Materials and methods
Patient characteristics
The McGill University Health Center (MUHC) is one of two
accredited centres in the province of Quebec, Canada, for the
treatment of complex hepatobiliary disease. Two cohorts were
studied: the first (‘original cohort’) consisted of all patients pre-
senting from January 2001 to December 2006 (n = 94) with
pathological or radiological evidence of pancreatic adenocarci-
noma and who were found on radiology or at laparotomy to
have unresectable disease. This cohort was used to create the
McGill–Brisbane Symptom Score (MBSS) presented below. A
second cohort (‘validation cohort’) of patients diagnosed with
UPA in 2007 and meeting similar criteria was used to validate
the MBSS (n = 32). Imaging in all patients consisted of com-
puted tomography scans with a triphasic pancreas protocol;
patients who were found to have metastasis or local invasion on
radiology were not offered bypass surgery and underwent endo-
scopic biliary stenting as appropriate. All patients selected for
surgery therefore underwent a laparotomy with a curative intent.
The findings of UPA at laparotomy, resulting either from local
invasion of major arterial vessels (coeliac artery or superior
mesenteric artery) or distant metastasis, confirmed the indica-
tion for palliation with a bypass (either choledochojejunostomy,
gastrojejunostomy or both [i.e. a ‘double bypass’]). In most situ-
ations, a double bypass was performed. The surgical team con-
sisted in all cases of an experienced hepatobiliary surgeon and a
fellow or chief resident. Endoscopic stent insertion was per-
formed by an endoscopist experienced in interventional endo-
scopic retrograde cholangiopancreatography. All patients
received antibiotic prophylaxis 30 min before stent insertion. A
plastic stent was inserted if the resectability of the patient had
not yet been determined; otherwise a metal non-covered stent
was inserted.
Preoperative data collection
Data on operative technique and findings, endoscopic procedures,
preoperative symptoms and radiological investigations were col-
lected using the MUHC prospective tumour registry database and
by chart review. Admission notes, attending staff letters and nutri-
tion consults were used to determine preoperative symptoms.
These included jaundice (bilirubin more than five times the
normal limit), self-reported weight loss of >10%, persistent
abdominal or back pain, onset of diabetes mellitus within 1 year
of diagnosis, and history of cigarette smoking within 5 years of
diagnosis.
The actual date of death was confirmed in all patients (n = 94)
in the original cohort by accessing the Government of Quebec
Registry. In the validation cohort (n = 32), however, date of last
contact was used to estimate survival as censored data via the
Kaplan–Meier method. Survival was calculated from the date of
diagnosis (the date with the first radiological evidence of pancre-
atic adenocarcinoma) to the date of death or last follow-up if the
patient was still alive at the time of the study.
Statistical analyses
Original cohort
In the original cohort, univariate analysis was conducted to
describe the distributions of baseline variables. Survival analysis
was then performed with a view towards construction of a
‘symptom score’.
(i) The McGill–Brisbane Symptom Score. Survival curves were
plotted and survival times estimated using the Kaplan–Meier
method with the Greenwood13 procedure to estimate median
survival and confidence intervals (CIs) in months. To avoid
variable selection caused by spurious correlations, variables
were excluded as potential predictors based on a visual exami-
nation of survival curves. Univariate tests of significance were
not used to build the model because they lack power, but in
the multivariable model we used a P-value of <0.1 in the
realization that small datasets may not necessarily have suffi-
cient power to detect the significance of small effects that
cumulatively may affect prognosis. Only factors obtained
early in diagnosis were used for the symptom score develop-
ment, which was based on a forward stepwise Cox propor-
tional hazards model. Results of this modelling were used to
weigh each of these components and develop the MBSS. Two
risk groups were created from the score – low intensity and
high intensity MBSS – as we felt that more than two groups
(e.g. tertiles or quartiles) would have less clinical relevance.
Having created this clinical score, we evaluated the strength of
its association with cancer-specific survival compared with
that of conventional predictors.
(ii) Predictors of cancer-specific survival. Exploratory analyses
were conducted using both binomial logistic regression and
Cox regression analyses with cancer-specific survival as the
outcome. Nine variables that impact on survival were identi-
fied: age; gender; tumour size; MBSS; presence of metastases;
local invasion alone; use of surgical bypass; use of endoscopic
bypass, and use of chemotherapy. Multivariable analysis was
used to identify independent predictors of survival. The
analysis was carried out by inserting one variable in themodel
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and then using forward stepwise regression to obtain a final
model. Odds ratios (ORs) and 95% CIs for all individual
variables in the final model were estimated. Significance state-
ments refer to P-values of <0.05 in two-tailed tests, except for
model building, in which P < 0.1 applied. We used spss for
Windows (Version 13; SPSS, Inc., Chicago, IL, USA) for all
statistical analyses.
Validation cohort
In the validation cohort, univariate analysis was conducted to
describe the distributions of baseline variables. In order to
validate the usefulness of the MBSS, we assessed its ability to
discriminate survival using the Kaplan–Meier method with the
Greenwood13 procedure to estimate median survival (and 95%
CI) in months.
Results
Original cohort
Baseline characteristics of the 94 original cohort patients are
shown in Table 1. Of these, 71 had a lesion located in the head of
the pancreas. The overall median survival in this cohort was 9.0
months. The actual survival associated with traditional predictors
of survival in this cohort is illustrated in Table 2. Table 3 shows the
results of the regression model that led to the creation of the
MBSS. Eventually, four factors were identified: weight loss of
>10% of body weight; smoking; pain, and jaundice. The resulting
continuous distribution of total risk scores across all patients in
the model (range 0–21) was used for the exploratory analysis. It
was then stratified into two equal categories (0–9 and 12–21) that
grouped patients according to their MBSS values (Table 4).
Results regarding the low and high intensity MBSS groups are
shown in Table 2 and Fig. 1(A). Survival by MBSS category
remained discriminatory even after patients were divided into
local invasion and metastatic disease subgroups (Table 5), which
suggests that the MBSS is a better discriminator than radiological
staging.
Table 1 Patient characteristics (n = 126, 2001–2007)
Variable Original cohort
2001–2006 (n = 94)
n (%)
Validation cohort
2007 (n = 32)
n (%)
Age, years
Median 69.0 68.5
Range 40–96 41–87
Sex
Men 53 (56) 15
Women 41 (44) 17
Tumour size, cm
Median 3.80 3.95
Range 1–10.0 1–6.6
Missing data n = 6 n = 8
Palliative intervention
Stent 24 (26) 21 (66)
Bypass 42 (45) 8 (25)
Both 1 (1) 0
None 27 (29) 3 (9)
Presenting symptoms
Weight loss (any) 71 (76) 22 (69)
Weight loss of >10% 55 (59) 22 (69)
Smoking 25 (27) 11 (34)
Pain 52 (55) 24 (75)
Jaundice 56 (60) 21 (66)
Table 2 Overall survival data for the original cohort (Kaplan–Meier)
(n = 94, 2001–2006)
Subgroups Median
survival,
months
95% CI
Local invasion only 10.3 6.1–14.5
Distant metastasis 6.6 4.2–9.0
Surgical palliation 9.1 6.9–11.3
Endoscopic palliation 7.0 2.4–11.6
No palliative intervention 13.0 8.8–17.2
Low intensity symptoms 14.6 13.1–16.1
High intensity symptoms 6.3 4.1–8.5
Overall 9.0 7.6–10.4
Table 3 Symptoms that independently predict survival (n = 94,
2001–2006) (odds that a patient with the symptom of interest
reaches the endpoint [death] first)a,b
Odds ratio P-value Hazard ratio
Weight loss of >10% 0.811 <0.001 2.2
Pain 0.511 0.025 1.7
Jaundice 0.398 0.087 1.5
Smoker 0.393 0.092 1.5
aAny weight lost, use of narcotics, cholangitis and recent or new diabetes
mellitus were not selected in the model
bVariables with P < 0.1 were included in the initial model in a stepwise
manner, starting with the variable with the lowest P-value. A standard
Cox regression was then run on the selected variables
Table 4 McGill–Brisbane Symptom Score (MBSS)
Symptom Points
Weight loss of >10% 8
Pain 5
Jaundice 4
Smoking 4
Total possible 21
Low intensity 0–9 (median 5, IQR 4.0–8.0)
High intensity 12–21 (median 13, IQR 12.5–17.0)
IQR, interquartile range
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Validation cohort
Descriptive analyses of baseline variables in patients in the vali-
dation cohort were similar to those for the original cohort
(Table 1) except with respect to the method of palliation from
jaundice: the use of biliary stents was more common in the 2007
group. In assessing survival in this validation cohort, the MBSS
was again seen to be an excellent discriminator of survival
(Fig. 1B).
Subsequent analyses were performed on both cohorts pooled
together using actual survival for the original cohort and censored
survival for the validation cohort. Exploratory analyses on the
total cohort revealed that factors predicting survival to or beyond
median survival via logistic regression analysis were MBSS,
tumour size, age and chemotherapy in decreasing order of impor-
tance. Chemotherapy was associated with an increased chance of
survival, whereas the others were associated with decreased sur-
vival. Local invasion, involvement of more than one site and use of
either method of palliation of jaundice were not independently
associated with survival in this model. On Cox regression analysis,
however, survival was not only significantly worse in patients with
a higher MBSS (hazard ratio [HR] 2.9, 95% CI 1.8–4.5), but also
in endoscopically palliated patients (HR 2.1, 95% CI 1.2–3.8). The
discrepancy between the findings of the logistic and Cox regres-
sion models is related to the survival difference between stented
and other patients. This difference in survival became prominent
only 9 months after diagnosis, whereas chemotherapy, tumour
size and age made their maximum impact on survival before that
time.
Finally, we looked at the distribution of individual variables in
the two MBSS groups. In the low symptom (LS) MBSS group, the
most common variables in decreasing order were jaundice (25/
50), pain (22/50), smoking (7/50) and weight loss of >10% (4/50).
In the high symptom (HS) MBSS group, the most common vari-
ables in decreasing order were weight loss of >10% (73/76), pain
(54/76), jaundice (52/76) and smoking (29/76).
Discussion
Few reports in the literature have attempted to identify factors
associated with survival in patients with UPA.14,15 The paucity of
such studies is partly related to difficulties in obtaining complete
follow-up in this cohort of seriously debilitated patients. In this
study, we therefore used the validated Quebec-wide population
database to confirm follow-up data for the original cohort
patients until death. The median survival was 10.3 months in
patients with locally invasive disease and 6.6 months in patients
with metastasis, for an overall median survival of 9.0 months
(Table 2). This is longer than in prior historical cohorts and is in
keeping with recent reports showing an increase in survival in
UPA.16,17 The cause of this increase in survival is not clearly iden-
tified and is probably multifactorial. Gemcitabine therapy has
been shown in retrospective studies and randomized control trials
to increase survival.18,19 It is currently the standard chemothera-
peutic agent for treatment of UPA with distant metastases. Refine-
ments in surgical and endoscopic techniques have also improved
the palliation of patients with jaundice and duodenal obstruction
and may well affect survival. Jaundice affects quality of life and
survival through its associations with pruritis, anorexia, impaired
renal function and immunosuppression.20–22 Another factor pro-
moting survival may be the increased interest among oncology
specialists in cancer palliation, which leads to better supportive
care of patients with UPA.22 Whatever the cause of this increase in
survival may be, this newly observed longevity provides a unique
opportunity to study subgroups of UPA patients who previously
had universally dismal survival.23
Several factors that predict prolonged survival in patients with
UPA have been previously described. In a study at the MDAnder-
son Cancer Centre (Houston, TX, USA),24 which looked at
(A)
(B)
Figure 1 Cumulative proportion of patients surviving (Kaplan–Meier)
in the (A) original cohort (n = 94) and (B) validation cohort (n = 32).,
complete data; +, censored data; MBSS, McGill–Brisbane Symptom
Score
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patients with UPA without metastasis who received chemoradia-
tion therapy, Karnofsky performance scale (KPS) values and
weight loss of <5% of body weight were found to be associated
with overall survival on univariate analysis. The only independent
prognostic factor on multivariate analysis, however, was KPS
score.24 It correlated with both disease-free and overall survival.
The KPS is a functional impairment scale on which scores range
from 0 (dead) to 100 (normal, no complaints). A median survival
of 3.9 months was observed in patients with a KPS score of <80, as
opposed to 4.9 months in those with a KPS score of >80. This
discrimination is, however, obviously not very good, possibly
because the KPS is not specifically tailored towards pancreatic
cancer. Cubiella et al. investigated factors predictive of survival in
134 patients with UPA.25 Eight of 34 factors on univariate analysis
correlated with survival; these were: jaundice; toxic syndrome at
admission; serum cholesterol, iron and alanine aminotransferase
concentrations; leukocyte count; baseline Eastern Cooperative
Oncology Group (ECOG) performance status (measured on a
scale of 0–5, where 0 denotes perfect health and 5 denotes death),
and the presence of distant metastases. Cox regression analysis
identified the absence of metastasis and a preserved baseline
ECOG performance status as the only factors associated with
improved overall survival. These authors did not consider weight
loss in their model. Finally, a recent study by Muller et al.26 found
that ASA (American Society of Anesthesiologists) score, presence
of liver metastasis, pain, CA 19-9, and carcinoembryonic antigen
(CEA) levels were independent predictors of poor survival on
multivariate analysis. The presence of four or five of these risk
factors was associated with a median survival of 3.5 months,
whereas patients with none or only one of these risk factors had a
median survival of 13.5 months. Of note, the patients in this study
had all been candidates for the Whipple procedure and none had
undergone stenting as initial definitive palliation, indicating a
positive survival selection bias.
In the present study, the aim was to create a simple clinical score
that could discriminate survival in patients presenting with UPA,
based on preoperative data, in order to help tailor palliation. In the
original UPA cohort, patients in the LS score group (scores of 0–9)
were likely to survive on average more than twice as long as
patients in the HS score group (scores of 12–21) (Table 2). The
median actual survival of patients in the HS group was 6.3
months, whereas the median survival of patients in the LS group
was 14.6 months (Table 2). Indeed, the MBSS provided a better
discrimination of survival than even the radiological documenta-
tion of distant metastasis (Table 5). When both these predictors
were combined in a multivariable Cox regression model, the
MBSS had an HR of 2.7 (P < 0.001) compared with an HR of 1.3
(P = 0.22) for the radiological presence of distant metastases. This
does not mean that the presence of distant metastases does not
impact on survival, but, rather, that its impact is much smaller
than that of the MBSS. These findings were corroborated in a
separate population: the validation cohort of UPA patients from
2007 (Fig. 1B). A comparison of the MBSS with other conven-
tional predictors of survival in a logistic regression using both
UPA cohorts together showed the symptom score to have the
strongest association with survival (beyond 9 months), followed
by the use of chemotherapy and age.
The strength of the association between the MBSS and survival
is greater than that of conventional predictors and is intriguing
because it is not measurable through findings on imaging
(Table 5). We believe that it may reflect an expression of disease
burden by measuring its clinical rather than its radiological or
biochemical expression. It could thus act as a very useful tool early
in the clinical encounter of a UPA patient for the purposes of
directing and tailoring palliation on an individual basis. Currently,
nearly all UPA patients are indiscriminately offered palliation
through endoscopic stenting because this modality is believed to
be associated with lesser morbidity and mortality. However, it is
well documented that metal stents appear to have a median
patency of about 7 months.12 Upon blockage, the patient will
develop cholangitis, which is associated with morbidity and
decreased quality of life.5 This 7-month period is in fact much
shorter than the anticipated survival of a patient with an LSMBBS
value (14.6 months). Patients presenting with jaundice or
obstructive symptoms and lower MBBS values might thus be
better served by initial surgical palliation because of their
increased anticipated survival.
In conclusion, the McGill–Brisbane Symptom Score appears to
be useful and to have validity in predicting the survival of UPA
patients on clinical grounds. This ability could lead to a better
Table 5 Symptom scorea by disease group and survival
Group Criteria Median survival, months
Original cohort, locally invasive group (n = 51, 2001–2006)
A (lower intensity symptoms) Score 0–9 15.0
B (higher intensity symptoms) Score 12–21 8.0
Original cohort, metastatic cancer group (n = 43, 2001–2006)
A (lower intensity symptoms) Score 0–9 12.2
B (higher intensity symptoms) Score 12–21 4.2
aSymptom score is the sum of the following: weight loss of >10% = 8, otherwise 0; pain = 5, otherwise 0; jaundice = 4, otherwise 0; smoking = 4,
otherwise 0
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selection of palliative methods in these patients. Although the
system was validated in a separate cohort from the same institu-
tion, a broader validation across multiple centres is desirable.
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